FDA
FDA Articles
Aimmune shares dipped on Monday after the FDA's Allergenic Products Advisory Committee voted to support the use of AR101 (Palforzia) in children and teens with peanut allergy.
Published:
Last Updated:
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the rest of September and in October.
Published:
Last Updated:
Ardelyx shares dropped on Friday after the firm announced that the FDA has approved its treatment of irritable bowel syndrome with constipation in adults.
Published:
Last Updated:
Xeris Pharmaceuticals shares were halted briefly on Tuesday after the firm announced that it has received regulatory approval from the FDA for Gvoke, its treatment of severe hypoglycemia in pediatric...
Published:
Last Updated:
Intra-Cellular Therapies shares dipped on Tuesday after the firm released a disappointing update from the FDA concerning its treatment for schizophrenia.
Published:
Last Updated:
Acadia Pharmaceuticals shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint.
Published:
Last Updated:
Endo shares jumped on Friday after the company announced that it has submitted a Biologics License Application to the FDA for collagenase clostridium histolyticum for the treatment of cellulite in...
Published:
Last Updated:
Puma Biotechnology shares jumped early Wednesday after FDA news about Puma’s breast cancer treatment. However, Puma shares quickly fell off from this FDA sugar high.
Published:
Last Updated:
Moderna shares jumped late on Monday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893)...
Published:
Last Updated:
Vanda Pharma shares dropped early to start out the week after the frim announced that it received a Complete Response Letter from the FDA.
Published:
Last Updated:
Akari Therapeutics shares jumped on Wednesday after the firm announced that the FDA has granted Fast Track designation for its stem cell transplant treatment.
Published:
Last Updated:
Deciphera Pharma shares nearly doubled on Tuesday after the firm announced top-line results from its late-stage trial treating patients with gastrointestinal stromal tumors.
Published:
Last Updated:
Amarin shares dropped on Friday after the firm announced that it received notice from the FDA that delays a pending supplemental new drug application.
Published:
Last Updated:
Intra-Cellular saw its shares dip on Wednesday after the firm announced that the FDA has canceled a meeting scheduled for July 31 to discuss the New Drug Application for lumateperone for the...
Published:
Last Updated:
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Published:
Last Updated: